인쇄하기
취소

Noticeable directions of Green Cross towards anticancer drug development

Published: 2014-11-05 14:55:46
Updated: 2014-11-05 15:02:21

녹십자It is observed that Green Cross is moving in the right direction to develop anticancer drugs.

Green Cross announced on the 3rd that the Ministry of Food and Drug Safety approved the plan for Phase 1 Clinical Study of ‘GC1118’, an Epidemic Growth Factor Receptor (EGFR) targeted therapy. The achievement is Green Cross’s another stepping stone for development of anticancer drugs, followed after t...

Fees

- Email service daily and homepage access.
  1. $300 per month.
  2. 5 Email holders per each company.
  3. Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.